BHC
$5.01-0.02 (-0.40%)
Bausch Health Companies Inc.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company, develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, generic pharmaceuti...
Recent News
Bausch (BHC) Down 15.2% Since Last Earnings Report: Can It Rebound?
Bausch (BHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should Bausch Health’s Profit Return and 2026 Outlook Shift the Investment Case for BHC?
Bausch Health Companies recently reported fourth-quarter 2025 revenue of US$2,796 million and a net loss of US$112 million, alongside full-year 2025 revenue of US$10.27 billion and net income of US$157 million, while also recording a US$145 million goodwill impairment and issuing 2026 revenue guidance of US$10.63–US$10.88 billion. Against this backdrop, Bausch and its OraPharma dental unit marked the 25th anniversary of ARESTIN®, the only FDA-approved locally applied antibiotic adjunct for...
Separation Overhang Continues to Weigh on Bausch Health Companies Inc. (BHC) Outlook
Bausch Health Companies Inc. (NYSE:BHC) is among the 7 Oversold Pharma Stocks to Buy Now. Bausch Health Companies Inc. (NYSE:BHC) is one of the most oversold stocks. TheFly reported on February 19 that Bank of America raised its price target for Bausch + Lomb (BLCO) to $15 from $13 and kept an Underperform rating. The […]
Bausch Health Weighs China Aesthetics Push Against ARESTIN Milestone And Debt
Bausch Health Companies (NYSE:BHC) agreed to acquire Shibo's aesthetics distribution business in China, expanding its presence in that market. The company marked the 25th anniversary of its ARESTIN® product, highlighting its long-running role in the portfolio. ARESTIN® has been introduced into additional markets, including Canada and Puerto Rico, alongside adjustments to Bausch Health's capital structure. Bausch Health Companies, listed as NYSE:BHC, operates across eye health,...
Ironwood vs. Bausch Health: Which GI Drug Stock is a Better Pick Now?
IRWD has the edge over BHC with high Linzess demand and upbeat 2026 revenue outlook offsetting pipeline and pricing risks.